Humanin vs Vesilute
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: HN, HNG (S14G-humanin)
Humanin is a 24-amino-acid peptide encoded inside mitochondrial DNA (in the 16S rRNA gene), discovered in 2001 and named for its ability to protect human neurons from Alzheimer-related cell death. It was the first member of the mitochondrial-derived peptide family and is studied mainly for neuroprotection, cell survival, and metabolic and age-related disease. The honest status: it has the deepest preclinical evidence base of any mitochondrial peptide, but human therapeutic trials are essentially absent.
Also: ED Dipeptide, Glu-Asp
Vesilute is marketed as a Khavinson-style short peptide bioregulator aimed at the urinary bladder and lower urinary tract. Vendor sources cannot even agree on its sequence: some list a Glu-Asp dipeptide, others a Lys-Glu-Asp tripeptide. There are no approvals and, importantly, no peer-reviewed studies published specifically on a peptide called Vesilute, so almost everything written about it is extrapolated from the broader bioregulator family rather than direct evidence.
Key Comparison Insights
- Both peptides belong to the Anti-Aging category, suggesting similar primary applications.
- Humanin has stronger research evidence (Animal Studies) compared to Vesilute (Preclinical).
Detailed Comparison
| Attribute | Humanin | Vesilute |
|---|---|---|
| Category | Anti-Aging | Anti-Aging |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Humanin is fundamentally a cell-survival signal that blocks apoptosis, the programmed self-destruct cells run when stressed. It binds a trimeric receptor complex made of CNTFR, WSX-1, and gp130 on the cell surface, switching on JAK2/STAT3 survival signaling. Inside the cell it directly grabs the pro-apoptotic protein BAX and stops it from moving to the mitochondria and punching holes in the membrane, which is the step that would otherwise commit the cell to death. It also binds IGFBP-3, modulating IGF-1 signaling and further dialing down apoptosis, and it interacts with formyl peptide receptors. The throughline across all of these is the same: keep stressed cells alive and protect mitochondria. | The claimed mechanism is the generic Khavinson one applied to bladder tissue: a very small peptide that can enter the cell nucleus, interact with chromatin and gene promoter regions, and adjust the expression of genes involved in bladder wall and smooth-muscle function. The marketing narrative adds heterochromatin decondensation, reactivation of genes silenced with age, and reduced chronic inflammation. None of this is supported by published experiments on this specific compound. Treat the entire mechanism as an unverified hypothesis borrowed from related peptides, not an established pathway for Vesilute itself. |
| Common Dosing | 5-10 mg weekly divided into 2-3 injections 2-3x weekly (e.g., Monday, Wednesday, Friday) | 1-2 capsules (10-20 mg) daily 1-2x daily, before meals |
| Administration | Injection (route varies) | Oral capsules |
| Typical Duration | Variable | 30-day courses, repeat after 4-6 months |
| Best Time to Take | Morning | Morning, before meals |
Possible Side Effects May vary by individual |
|
|
| Research Summary | Humanin is one of the best-characterized mitochondrial peptides in the lab, with a large body of in vitro and animal work. It protects neurons against amyloid-beta toxicity, shields retinal pigment epithelium cells from oxidative stress and senescence, and shows protective effects in models of cardiovascular disease and diabetes. Circulating humanin declines with age in humans, and some studies link higher endogenous levels to better metabolic and longevity markers, which fuels the longevity interest. But that is association and animal data, not proof that taking humanin treats any disease. There are no large completed randomized human trials demonstrating clinical benefit, and most of what is sold to consumers is synthetic humanin or analogues like HNG, used far ahead of the evidence. It is a compelling research molecule, not a validated drug. | This is where Vesilute falls apart on scrutiny. A literature search turns up no controlled studies, no animal data, and no human trials carried out on a peptide named Vesilute. The supportive-sounding claims about bladder and prostate function are reasoned by analogy from other Khavinson cytomedin and cytogen peptides, which themselves rest largely on a single research lineage with limited independent replication. Because even the basic sequence is reported inconsistently across suppliers, you cannot be confident two products labeled Vesilute are the same molecule. There is no safety or efficacy evidence to support using it for urinary symptoms, bladder health, or anything else. Anyone presenting Vesilute as proven is overstating an almost entirely unstudied product. |
Frequently Asked Questions: Humanin vs Vesilute
What is the difference between Humanin and Vesilute?
Humanin is a anti-aging peptide that humanin is a 24-amino-acid peptide encoded inside mitochondrial dna (in the 16s rrna gene), discovered in 2001 and named for its ability to protect human neurons from alzheimer-related cell death. it was the first member of the mitochondrial-derived peptide family and is studied mainly for neuroprotection, cell survival, and metabolic and age-related disease. the honest status: it has the deepest preclinical evidence base of any mitochondrial peptide, but human therapeutic trials are essentially absent. Vesilute is a anti-aging peptide that vesilute is marketed as a khavinson-style short peptide bioregulator aimed at the urinary bladder and lower urinary tract. vendor sources cannot even agree on its sequence: some list a glu-asp dipeptide, others a lys-glu-asp tripeptide. there are no approvals and, importantly, no peer-reviewed studies published specifically on a peptide called vesilute, so almost everything written about it is extrapolated from the broader bioregulator family rather than direct evidence. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Humanin or Vesilute?
Neither is universally "better" - the choice depends on your specific goals. Humanin is typically used for anti-aging purposes, while Vesilute is used for anti-aging. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Humanin and Vesilute be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Humanin and Vesilute together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.